Natasha leads Seagen’s Corporate Development and Alliance Management effort. She has broad experience in corporate development, including licensing, venture capital, corporate strategy and mergers and acquisitions. Since joining Seagen, she has successfully executed numerous licensing and collaboration deals with major pharma partners. She was instrumental in bringing TUKYSA® (tucatinib), TIVDAK® (tisotumab vedotin), and disitamab vedotin into our pipeline, as well as the acquisition of Seagen’s manufacturing facility.
Previously, Natasha was a senior member of the mergers and acquisitions and corporate strategy team at Amgen, where she led a variety of Corporate Development and out-licensing efforts. While at Amgen, she also held roles in discovery, research project management, and business development finance.
Natasha earned an M.B.A. from Pepperdine University and a B.A. in Biology from University of California Santa Barbara. She serves as a member of the board of directors for Xoma Corporation and Alpine Immune Sciences Inc., and is a member of the External Advisory Board for the University of Oregon’s Knight Campus for Accelerating Scientific Impact.